Enzymatica AB (publ) (STO:ENZY)

Market Cap	514.60M
Revenue (ttm)	50.29M
Net Income (ttm)	-52.99M
Shares Out	242.74M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,625
Average Volume	99,915
Open	2.100
Previous Close	2.030
Day's Range	2.000 - 2.130
52-Week Range	1.340 - 5.450
Beta	0.11
RSI	37.96
Earnings Date	Oct 30, 2025

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company’s product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care. The company offers its products through contract organizations. Enzymatica AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ENZY

Financial Performance

In 2024, Enzymatica AB's revenue was 45.58 million, a decrease of -10.47% compared to the previous year's 50.90 million. Losses were -53.18 million, 6.94% more than in 2023.